Kavisha Arora
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kavisha Arora has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Anjaparavanda P. Naren
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA; Division of Pulmonary Medicine, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA; Karsh Division of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA
6 shared publications - Kyu Shik Mun
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
4 shared publications Joseph J. Palermo
3 shared publications- Anjaparavanda P. Naren
Department of Physiology, University of Tennessee Health Science Center, Memphis, Tennessee
2 shared publications - Jaimie D. Nathan
Department of Abdominal Transplant and Hepatopancreatobiliary Surgery Nationwide Children's Hospital Columbus Ohio USA
2 shared publications - Maisam Abu-El-Haija
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
2 shared publications
Latest Publications
- Open Access
- 1 August 2018
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 293 (33) , 12949-12959
AC6 is the major adenylate cyclase forming a diarrheagenic protein complex with cystic fibrosis transmembrane conductance regulator in cholera
- 1 August 2018
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 293 (33) , 12949-12959
Open AccessAC6 is the major adenylate cyclase forming a diarrheagenic protein complex with cystic fibrosis transmembrane conductance regulator in cholera
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
1017 - Guanylate Cyclase 2C Activation Rescues the Folding Defect in F508Del CFTR
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
1017 - Guanylate Cyclase 2C Activation Rescues the Folding Defect in F508Del CFTR
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Tu1372 - Developing Patient-Derived Pancreas-On-A-Chip to Study Cystic Fibrosis Related Diabetes
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Tu1372 - Developing Patient-Derived Pancreas-On-A-Chip to Study Cystic Fibrosis Related Diabetes
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
908 - Targeting a Novel ER Chaperone ERDJ4/DNAJB9 to Rescue Mutant CFTR in the Intestine
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
908 - Targeting a Novel ER Chaperone ERDJ4/DNAJB9 to Rescue Mutant CFTR in the Intestine
- Open Access
PP-2, a src-kinase inhibitor, is a potential corrector for F508del-CFTR in cystic fibrosis
Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. The most common mutation in CF, an in-frame deletion of phenylalanine 508, leads to a trafficking defect and endoplasmic reticulum retention of the protein where it becomes targeted for degradation. Successful clinical deployments of ivacaftor and ivacaftor/lumacaftor combination have been an exciting translational development in treating CF. However, their therapeutic effects are variable between subjects and remain insufficient. We used the Library of Integrated Network-based Cellular Signatures (LINCS) database as our chemical pool to screen for candidates. For in silico screening, we integrated connectivity mapping and CF systems biology to identify candidate therapeutic compounds for CF. Following in silico screening, we validated our candidate compounds with (i) an enteroid-based compound screening assay using CF (ΔF508/ΔF508-CFTR) patient-derived enteroids, (ii) short-circuit current analysis using polarized CF primary human airway epithelial cells and (iii) Western blots to measure F508-del-CFTR protein maturation. We identified 184 candidate compounds with in silico screening and tested 24 of them with enteroid-based forskolin-induced swelling (FIS) assay. The top hit compound was PP2, a known src-kinase inhibitor that induced swelling in enteroid comparable to known CF corrector (lumacaftor). Further validation with Western blot and short-circuit current analysis showed that PP-2 could correct mutant CFTR mis-folding and restore CFTR-mediated transmembrane current. We have identified PP2, a known src-kinase inhibitor, as a novel corrector of ΔF508-CFTR. Based on our studies and previous reports, src kinase inhibition may represent a novel paradigm of multi-action therapeutics – corrector, anti-inflammatory, and anti-infective – in CF.
Open AccessPP-2, a src-kinase inhibitor, is a potential corrector for F508del-CFTR in cystic fibrosis
Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. The most common mutation in CF, an in-frame deletion of phenylalanine 508, leads to a trafficking defect and endoplasmic reticulum retention of the protein where it becomes targeted for degradation. Successful clinical deployments of ivacaftor and ivacaftor/lumacaftor combination have been an exciting translational development in treating CF. However, their therapeutic effects are variable between subjects and remain insufficient. We used the Library of Integrated Network-based Cellular Signatures (LINCS) database as our chemical pool to screen for candidates. For in silico screening, we integrated connectivity mapping and CF systems biology to identify candidate therapeutic compounds for CF. Following in silico screening, we validated our candidate compounds with (i) an enteroid-based compound screening assay using CF (ΔF508/ΔF508-CFTR) patient-derived enteroids, (ii) short-circuit current analysis using polarized CF primary human airway epithelial cells and (iii) Western blots to measure F508-del-CFTR protein maturation. We identified 184 candidate compounds with in silico screening and tested 24 of them with enteroid-based forskolin-induced swelling (FIS) assay. The top hit compound was PP2, a known src-kinase inhibitor that induced swelling in enteroid comparable to known CF corrector (lumacaftor). Further validation with Western blot and short-circuit current analysis showed that PP-2 could correct mutant CFTR mis-folding and restore CFTR-mediated transmembrane current. We have identified PP2, a known src-kinase inhibitor, as a novel corrector of ΔF508-CFTR. Based on our studies and previous reports, src kinase inhibition may represent a novel paradigm of multi-action therapeutics – corrector, anti-inflammatory, and anti-infective – in CF.
- Open Access
- 5 October 2017
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 2 (19)
Guanylate cyclase 2C agonism corrects CFTR mutants
Cystic fibrosis (CF) is a genetic disorder in which epithelium-generated fluid flow from the lung, intestine, and pancreas is impaired due to mutations disrupting CF transmembrane conductance regulator (CFTR) channel function. CF manifestations of the pancreas and lung are present in the vast majority of CF patients, and 15% of CF infants are born with obstructed gut or meconium ileus. However, constipation is a significantly underreported outcome of CF disease, affecting 47% of the CF patients, and management becomes critical in the wake of increasing life span of CF patients. In this study, we unraveled a potentially novel molecular role of a membrane-bound cyclic guanosine monophosphate–synthesizing (cGMP-synthesizing) intestinal enzyme, guanylate cyclase 2C (GCC) that could be targeted to ameliorate CF-associated intestinal fluid deficit. We demonstrated that GCC agonism results in functional rescue of murine F508del/F508del and R117H/R117H Cftr and CFTR mutants in CF patient–derived intestinal spheres. GCC coexpression and activation facilitated processing and ER exit of F508del CFTR and presented a potentially novel rescue modality in the intestine, similar to the CF corrector VX-809. Our findings identify GCC as a biological CFTR corrector and potentiator in the intestine.
- 5 October 2017
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 2 (19)
Open AccessGuanylate cyclase 2C agonism corrects CFTR mutants
Cystic fibrosis (CF) is a genetic disorder in which epithelium-generated fluid flow from the lung, intestine, and pancreas is impaired due to mutations disrupting CF transmembrane conductance regulator (CFTR) channel function. CF manifestations of the pancreas and lung are present in the vast majority of CF patients, and 15% of CF infants are born with obstructed gut or meconium ileus. However, constipation is a significantly underreported outcome of CF disease, affecting 47% of the CF patients, and management becomes critical in the wake of increasing life span of CF patients. In this study, we unraveled a potentially novel molecular role of a membrane-bound cyclic guanosine monophosphate–synthesizing (cGMP-synthesizing) intestinal enzyme, guanylate cyclase 2C (GCC) that could be targeted to ameliorate CF-associated intestinal fluid deficit. We demonstrated that GCC agonism results in functional rescue of murine F508del/F508del and R117H/R117H Cftr and CFTR mutants in CF patient–derived intestinal spheres. GCC coexpression and activation facilitated processing and ER exit of F508del CFTR and presented a potentially novel rescue modality in the intestine, similar to the CF corrector VX-809. Our findings identify GCC as a biological CFTR corrector and potentiator in the intestine.
- Open Access
- 2 June 2017
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 2 (11)
Epithelial Gpr116 regulates pulmonary alveolar homeostasis via Gq/11 signaling
Pulmonary function is dependent upon the precise regulation of alveolar surfactant. Alterations in pulmonary surfactant concentrations or function impair ventilation and cause tissue injury. Identification of the molecular pathways that sense and regulate endogenous alveolar surfactant concentrations, coupled with the ability to pharmacologically modulate them both positively and negatively, would be a major therapeutic advance for patients with acute and chronic lung diseases caused by disruption of surfactant homeostasis. The orphan adhesion GPCR GPR116 (also known as Adgrf5) is a critical regulator of alveolar surfactant concentrations. Here, we show that human and mouse GPR116 control surfactant secretion and reuptake in alveolar type II (AT2) cells by regulating guanine nucleotide–binding domain α q and 11 (G q/11 ) signaling. Synthetic peptides derived from the ectodomain of GPR116 activated G q/11 -dependent inositol phosphate conversion, calcium mobilization, and cortical F-actin stabilization to inhibit surfactant secretion. AT2 cell–specific deletion of Gnaq and Gna11 phenocopied the accumulation of surfactant observed in Gpr116 –/– mice. These data provide proof of concept that GPR116 is a plausible therapeutic target to modulate endogenous alveolar surfactant pools to treat pulmonary diseases associated with surfactant dysfunction.
- 2 June 2017
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 2 (11)
Open AccessEpithelial Gpr116 regulates pulmonary alveolar homeostasis via Gq/11 signaling
Pulmonary function is dependent upon the precise regulation of alveolar surfactant. Alterations in pulmonary surfactant concentrations or function impair ventilation and cause tissue injury. Identification of the molecular pathways that sense and regulate endogenous alveolar surfactant concentrations, coupled with the ability to pharmacologically modulate them both positively and negatively, would be a major therapeutic advance for patients with acute and chronic lung diseases caused by disruption of surfactant homeostasis. The orphan adhesion GPCR GPR116 (also known as Adgrf5) is a critical regulator of alveolar surfactant concentrations. Here, we show that human and mouse GPR116 control surfactant secretion and reuptake in alveolar type II (AT2) cells by regulating guanine nucleotide–binding domain α q and 11 (G q/11 ) signaling. Synthetic peptides derived from the ectodomain of GPR116 activated G q/11 -dependent inositol phosphate conversion, calcium mobilization, and cortical F-actin stabilization to inhibit surfactant secretion. AT2 cell–specific deletion of Gnaq and Gna11 phenocopied the accumulation of surfactant observed in Gpr116 –/– mice. These data provide proof of concept that GPR116 is a plausible therapeutic target to modulate endogenous alveolar surfactant pools to treat pulmonary diseases associated with surfactant dysfunction.
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S17-S18
Patient-Derived Pancreatic Ductal Organoids to Study CFTR Function
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S17-S18
Patient-Derived Pancreatic Ductal Organoids to Study CFTR Function
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Mo2029 Asymmetric Compartmentalization of LPA2 Receptors on Plasma Membrane Mediate Gradient Sensing of Fibroblast
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Mo2029 Asymmetric Compartmentalization of LPA2 Receptors on Plasma Membrane Mediate Gradient Sensing of Fibroblast